We are live on ! Find out more
RG

Redmile Group Portfolio holdings

AUM $1.51B
1-Year Est. Return 164.17%
This Fund
S&P 500
This Quarter Est. Return
+9.38%
1 Year Est. Return
+164.17%
3 Year Est. Return
+929.47%
5 Year Est. Return
+823.75%
10 Year Est. Return
+18,826.17%
AUM
$5.45B
AUM Growth
+$30.2M
Cap. Flow
+$53.1M
Cap. Flow %
0.97%
Top 10 Hldgs %
47.61%
Holding
95
New
15
Increased
22
Reduced
33
Closed
14

Top Buys

Rank Stock Value
1
GILD icon
Gilead Sciences
GILD
+$199M
2
OSH
Oak Street Health, Inc.
OSH
+$119M
3
KYMR icon
Kymera Therapeutics
KYMR
+$83.4M
4
ANNX icon
Annexon
ANNX
+$80.8M
5
KLRS
Kalaris Therapeutics
KLRS
+$69.3M

Top Sells

Rank Stock Value
1
PRNB
Principia Biopharma Inc. Common Stock
PRNB
+$162M
2
MNTA
Momenta Pharmaceuticals, Inc.
MNTA
+$157M
3
BNTX icon
BioNTech
BNTX
+$132M
4
HRC
HILL-ROM HOLDINGS, INC.
HRC
+$64.2M
5
CYRX icon
CryoPort
CYRX
+$55M

Sector Composition

Rank Sector Weight
1 Healthcare 92.54%
2 Financials 0.5%
3 Technology 0%
4 Industrials 0%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
RIGL icon
76
Rigel Pharmaceuticals
RIGL
$741M
$1.79M 0.03%
+74,458
New +$1.83M
WVE icon
77
Wave Life Sciences
WVE
$1.14B
$1.39M 0.03%
163,619
-251,536
-61% -$2.76M
VAPO
78
DELISTED
Vapotherm, Inc. Common Stock
VAPO
$725K 0.01%
3,125
– –
OVID icon
79
Ovid Therapeutics
OVID
$455M
$700K 0.01%
121,950
– –
ODT
80
DELISTED
Odonate Therapeutics, Inc. Common Stock
ODT
$338K 0.01%
25,162
-607,876
-96% -$17.2M
CSLT
81
DELISTED
CASTLIGHT HEALTH, INC.
CSLT
$12K ﹤0.01%
10,229
– –
BNR
82
Burning Rock Biotech
BNR
$106M
– –
-13,393
Closed -$3.62M
CYRX icon
83
CryoPort
CYRX
$821M
– –
-1,817,663
Closed -$55M
GH icon
84
Guardant Health
GH
$20.6B
– –
-297,619
Closed -$24.1M
GMAB icon
85
Genmab
GMAB
$17.5B
– –
-1,057,393
Closed -$35.8M
MRK icon
86
Merck
MRK
$314B
– –
-549,466
Closed -$40.5M
NVS icon
87
Novartis
NVS
$292B
– –
-439,800
Closed -$38.4M
RPRX icon
88
Royalty Pharma
RPRX
$26.1B
– –
-200,000
Closed -$9.71M
TWST icon
89
Twist Bioscience
TWST
$5.78B
– –
-589,300
Closed -$26.7M
UNH icon
90
UnitedHealth
UNH
$382B
– –
-103,900
Closed -$30.6M
HRC
91
DELISTED
HILL-ROM HOLDINGS, INC.
HRC
– –
-585,000
Closed -$64.2M
BMY.RT
92
DELISTED
Bristol-Myers Squibb Company Contingent Value Rights
BMY.RT
– –
-2,467,000
Closed -$8.83M
MNTA
93
DELISTED
Momenta Pharmaceuticals, Inc.
MNTA
– –
-4,705,308
Closed -$157M
PRNB
94
DELISTED
Principia Biopharma Inc. Common Stock
PRNB
– –
-2,712,388
Closed -$162M
ELGX
95
DELISTED
Endologix Inc
ELGX
– –
-78,755
Closed -$63K
1 2 3
4

Similar funds

ORI
Oak Ridge Investments Chicago, Illinois $1.51B AUM 37.25% 1-Year Est. Return
KP
Keel Point Huntsville, Alabama $1.51B AUM 20.06% 1-Year Est. Return
FMI
F/M Investments Washington, District of Columbia $1.51B AUM 25.86% 1-Year Est. Return
FCM
Fairholme Capital Management South Miami, Florida $1.51B AUM 28.27% 1-Year Est. Return
SCM
SG Capital Management Chicago, Illinois $1.51B AUM 49.98% 1-Year Est. Return
PP
PDS Planning Dublin, Ohio $1.52B AUM 18.08% 1-Year Est. Return
AM
Ares Management Los Angeles, California $1.52B AUM 12.97% 1-Year Est. Return
BFO
Boston Family Office Boston, Massachusetts $1.5B AUM 11.68% 1-Year Est. Return

Redmile Group's Q3 2020 Portfolio in Review

As of Q3 2020, Redmile Group held 95 positions worth $5.45B, up 0.56% from $5.42B the previous quarter. Its ten largest holdings account for 48% of the portfolio.

Redmile Group's Q3 2020 filing shows 15 new, 22 increased, 33 reduced and 14 closed positions. Its largest new stake was Gilead Sciences: 2,869,962 shares worth $181M. The largest sale was Principia Biopharma Inc. Common Stock, an estimated $162M.

By sector, the portfolio is most concentrated in Healthcare at 93% of assets, down from 93% a quarter earlier, followed by Financials and Technology.

  • Redmile Group's largest Q3 2020 buy was Gilead Sciences: 2,869,962 shares worth $181M.
  • Redmile Group added most to Akero Therapeutics in Q3 2020, an estimated $67.9M increase.
  • Redmile Group's biggest Q3 2020 reduction was BioNTech, cutting an estimated $132M.
  • Redmile Group fully exited Principia Biopharma Inc. Common Stock in Q3 2020, selling an estimated $162M.
  • Redmile Group's ten largest holdings make up 48% of its $5.45B portfolio in Q3 2020.
  • Redmile Group opened 15 new positions and closed 14 in Q3 2020.
  • Redmile Group's portfolio value rose 0.56% quarter-over-quarter to $5.45B.

Based on Redmile Group's 13F filing for Q3 2020, filed 16 Nov 2020.